Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke

Author(s): Shan Wang, Fei Ma, Longjian Huang, Yong Zhang, Yuchen Peng, Changhong Xing, Yipu Feng, Xiaoliang Wang*, Ying Peng*

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 17 , Issue 5 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background and Objective: Stroke is a leading cause of morbidity and mortality in both developed and developing countries all over the world. The only drug for ischemic stroke approved by FDA is recombinant tissue plasminogen activator (rtPA). However, only 2-5% stroke patients receive rtPAs treatment due to its strict therapeutic time window. As ischemic stroke is a complex disease involving multiple mechanisms, medications with multi-targets may be more powerful compared with single-target drugs. Dl-3-n-Butylphthalide (NBP) is a synthetic compound based on l-3-n- Butylphthalide that is isolated from seeds of Apium graveolens. The racemic 3-n-butylphthalide (dl- NBP) was approved by Food and Drug Administration of China for the treatment of ischemic stroke in 2002. A number of clinical studies indicated that NBP not only improved the symptoms of ischemic stroke, but also contributed to the long-term recovery. The potential mechanisms of NBP for ischemic stroke treatment may target different pathophysiological processes, including anti-oxidant, antiinflammation, anti-apoptosis, anti-thrombosis, and protection of mitochondria et al.

Conclusion: In this review, we have summarized the research progress of NBP for the treatment of ischemic stroke during the past two decades.

Keywords: Dl-3-n-butylphthalide, ischemic stroke, cerebral microcirculation, neuroprotection, mitochondria, apoptosis, oxidative stress.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 07 August, 2018
Page: [338 - 347]
Pages: 10
DOI: 10.2174/1871527317666180612125843
Price: $65

Article Metrics

PDF: 84
HTML: 19
PRC: 4